Skip to main content
Home
  • Clinical Outcome Assessments
    Clinical Outcome Assessments

    What are Clinical Outcome Assessments (COAs)? What do they measure?

    Learn more about COAs
    hero_1.jpeg
    The most trusted distributor of COAs

    700+ exclusive COA distributions on behalf of their copyright owners

    hero_2.jpeg
    PROQOLID™: the largest COA database

    7,000+ COAs described in details and accessible in this unique database

  • Services
    Services

    Mapi Research Trust provides turnkey solutions for your Clinical Outcome Assessments (COAs) strategies - including COA databases, targeted literature reviews, licensing.

    Read More
    COA Databases Patient-Centered Endpoint Intelligence COA Licensing Translation and Linguistic Validation eCOA Licensing COA Repository
    hero_3.jpeg
    About ePROVIDE™

    Online access to all our services and COA databases

    hero_2_2.jpeg
    What are eBooklets?

    Find out more about this step-by-step guidance for valid digitization of COAs

  • Author Collaboration
    Author Collaboration

    Our team is dedicated to assisting authors in the daily management of their questionnaires and all derivatives, including translations and electronic versions

    Read More
    COA distribution COA copyright and protection Promotion of COAs and developers Testimonials
    hero_3_1.jpeg
    Catalog of COAs distributed by Mapi Research Trust

    800+ exclusive distributions of COAs, accessible in ePROVIDE

  • Resources
    Resources

    ACCESS all our resources on COAs and eCOA: webinars, publications, blogs. SUBSCRIBE to receive email updates.

    Read More
    Blog Publications Useful links Webinar recordings Whitepapers
    Whitepaper-Digitizing-COAs.jpg
    New whitepaper

    Digitizing COAs: A streamlined approach to approval

    hero_4_2.jpeg
    New whitepaper

    COAs and copyright: How to mitigate risks of infringement and misuse in clinical research and practice

  • News & Events
    News & Events

    Stay informed with our latest news and check all our upcoming events. SUBSCRIBE to get email updates.

    Read More
    hero_5_1.jpeg
    News
    Hero_5_2.jpeg
    Conferences
    Hero_5_3.jpeg
    Webinars
  • About us
    About us

    Mapi Research Trust is a non-profit organization dedicated to improving patients’ quality of life by facilitating access to Clinical Outcome Assessments(COAs).

    Read More
    hero_6_1.jpeg
    Team

    A global team of multi-disciplinary experts

    hero_6_2.jpeg
    Experience

    Collecting & Processing Patient Centered Outcomes information for more than two decades

  • Contact
  1. Home
  2. News & Events
  3. News
  4. Access to treatment: unequal care for European rare disease patients

Access to treatment: unequal care for European rare disease patients

Access to treatment: unequal care for European rare disease patients

Authors: Sandra Courbier, Rare Barometer Leader1; Erwan Berjonneau, Rare Barometer Research Executive1; François Houyez, Treatment Information and Access Director, Health Policy Advisor1; Xavier Fournie, Corporate Medical Director & Exec VP, Global Medical Affairs2
1EURORDIS, Paris, France; 2Mapi, Lyon, France
 

Introduction

In 1999, the European Union regulation on orphan medicinal products stated “patients suffering from rare conditions should be entitled to the same quality of treatment as other patients”1
Today, the issue of access to medical treatments is under pressure due to a number of recent developments including the economic crisis, leading to falling healthcare spending in many Member States, and an ageing population.
As for rare diseases, only a very small number of them have curative treatment. However, what is the level of access for existing rare disease treatments, either symptomatic or disease-modifying? Does it really differ from the general population?
To answer these questions, EURORDIS carried out a survey through its Rare Barometer Survey Programme (http://www.eurordis.org/rare-barometer-programme). Rare Barometer participants, i;e., patients affected by a rare disease, their parents, siblings or other family members and carers, and patient representatives who answer regularly to EURORDIS surveys, were asked about access to treatments.
 

Methods

Fieldwork started on 11th of February and ended on 16th of February 2017.
The question referred to medical treatment in general including medicines (disease modifiers and symptomatic treatments), surgery and medical devices. EURORDIS researchers used question 20 from the International Social Survey Programme (ISSP) focused on health and health care2 (See Figure 1). The ISSP is a continuing annual programme of cross-national collaboration on surveys covering topics important for social science research. The last wave regarding health care was carried out in 2011. Comparison were made with the results of the European continent.


Figure 1. Question 20 from the ISSP health and health care 2011 survey

uuid_9ab5b04c-e32f-42ce-b673-f0e70f9901cf_Fig1-300x142_access-treatment-1

For the Rare Barometer survey, a Yes/No response option was used, with “No” corresponding to: No it didn’t happened/No need of medical treatment/Non response.
 

Results

A total of 1350 persons from 21 European Countries responded to the survey. The sample was composed of 54% of patients and 46% of carers (i.e., parents, siblings or other family members, carers and patient representatives). Carers answered in relation with the situation of the patient they care for. Patient representatives are frequently also patients or patients’ relatives and they represented only 5.6% of the respondents (12% of the carers category) thus had a limited impact on global responses.
24% of the rare disease sample declared that during the past 12 months they did not get the medical treatment they needed because the treatment was not available in their country (See Figure 2). The difference with the general population is striking as it is 17% higher. The gap between the general population and rare disease patients was reported as even deeper in some countries such as in the United Kingdom where 31% say that the treatment was unavailable in their country compare to only 3% of the general population.


Figure 2. Results with Response “Treatment not available”

uuid_41a9ca70-7c14-4403-8243-3353b9b59a6c_Fig2-300x192_access-treatment-2

When asked if they did not get the medical treatment they needed because they were not able to pay for it, 15% of the respondent answered yes (see Figure 3). This represents a difference of 9 percentage points compared to the general population.
Figure 3. Results with Response “Could not pay for it”

uuid_fa95580c-2089-41cd-ae45-ed3a705fa66e_Fig3-300x186_access-treatment-3

19% answered yes when asked if they were prevented from accessing the treatment they need because the waiting list was too long (see Figure 4). There is a marked difference in comparison to the general population: 10% percentage points more. This waiting time is mainly related to the time required to obtain a visit or appropriate hospitalisation.
Figure 4. Results with Response “Waiting list too long”

uuid_32e7a397-2b0c-46e8-9035-3e32e82fc6c9_Fig4-300x185_access-treatment-4

Conclusion

Compared to the general population, rare disease patients have a lower level of access to treatment. Efforts still need to be made to  fulfil the needs of people living with a rare disease while maintaining the sustainability of the European healthcare systems.
 

References

Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal L 018, 22/01/2000 P. 0001 – 0005. Available at: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32000R0141. Last accessed April 19, 2017.
http://www.issp.org/data-download/by-topic/. Last accessed April 19, 2017.

 
For more information, please contact Sandra Courbier, Surveys and Social Studies Manager, Rare Barometer Leader: sandra.courbier@eurordis.org
 

Acknowledgments

Special thanks to the Rare Barometer Participants and all Rare Barometer Partners:

uuid_439365d6-60d5-49a9-92ff-b3343f944bee_Rara-barometer-partners-300x122_access-treatment-acknowledge
In this section
In this section
  • News
  • Events
    • Conferences
    • Webinars
Site Branding
    ICON plc
  • Contact
  • About Us
For Clients
  • Services
  • Resources
  • ePROVIDE™
News & Events
  • News
  • Conferences
  • Webinars
Socials
  • Linkedin

Legal Footer

  • © 2025 Mapi Research Trust
  • Disclaimer
  • Privacy
  • Site Cookies
How can we help?
  • All
Popular search terms:
  • COVID-19
  • Site & Patient Recruitment
  • Oncology
  • Medical Device
  • Real World Evidence
  • Decentralised & hybrid clinical trials
  • Digital Disruption